After thyroid eye drug scores in PhIII test, Horizon Pharma readies marketing application
Less than two years after Horizon Pharma $HZNP procured phase III-ready thyroid eye disease (TED) drug teprotumumab for $145 million upfront by acquiring a unit of Narrow River, biotech veteran David Madden’s investment firm — the bet has paid off, as the autoimmune inflammatory disorder drug passed its late-stage test on Thursday.
In TED patients, the eye muscles and fatty tissue behind the eye become inflamed, causing the eyes to appear to be ‘bulging’ and eyelids to become swollen and red, eventually culminating in eye misalignment, double vision and in some cases even blindness — but there is limited window of up to three years during which the condition can be treated without surgical intervention.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.